Conatus Achieves Positive Results with Emricasan in Initial Stage of Phase 2 Liver Cirrhosis Clinical Trial

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/15/2026

1. SPY
2. CRWV
3. BAC
4. NVDA
5. RKLB
6. BLK
7. CAT
8. RXRX
9. NOW
10. FMC

Go back to Conatus Achieves Positive Results with Emricasan in Initial Stage of Phase 2 Liver Cirrhosis Clinical Trial

Roth Capital Reiterates Buy Following Conatus Pharmaceuticals (CNAT) Phase II Emricasan Data

January 6, 2016 9:26 AM EST

Roth Capital reiterated a Buy rating and $15.00 price target on Conatus Pharmaceuticals (NASDAQ: CNAT) following the company's reported three-month data from its double-blind, placebo-controlled Phase 2 trial in liver cirrhosis patients. The data indicated that there is a significant functional benefit for severe cirrhotic patients treated with emricasan.

Analyst Elemer Piros commented,... More

Conatus Pharmaceuticals (CNAT) Resumes Trading; Shares Up 10%

January 5, 2016 4:38 PM EST

Conatus Pharmaceuticals (NASDAQ: CNAT) resumed trading and is up 9.8% after announcing that the three-month, double-blind, placebo-controlled stage... More

Conatus Pharmaceuticals (CNAT) to Resume Trading at 4.35 PM ET

January 5, 2016 4:11 PM EST

Conatus Pharmaceuticals (NASDAQ: CNAT) to Resume Trading at 4.35 PM ET

... More